(Q35680592)

9 August 2017

1 reference

title

Managing the symptoms of Behçet's disease (English)

1 reference

9 August 2017

0 references

Cem Evereklioglu

1

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 February 2004

1 reference

Expert Opinion on Pharmacotherapy

9 August 2017

published in

1 reference

9 August 2017

volume

5

1 reference

9 August 2017

issue

2

1 reference

9 August 2017

page(s)

317-328

1 reference

Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet's disease

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

Adenosine deaminase enzyme activity is increased and negatively correlates with catalase, superoxide dismutase and glutathione peroxidase in patients with Behçet's disease: original contributions/clinical and laboratory investigations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

HLA antigens in Behçet's disease: a reappraisal by a comparative study of Turkish and British patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

Behçet's disease: infectious aetiology, new autoantigens, and HLA-B51

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

Behçet's disease: an enigmatic vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

The multiple faces of Behçet's disease and its aetiological factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

Influence of age of onset and patient's sex on the prevalence and severity of manifestations of Behçet's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

Behçet's syndrome with arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

Neurologic involvement in seven patients with Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

Novel approaches to Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

Thalidomide in Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

A comparative study of the pathergy reaction among Turkish and British patients with Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

The pathergy test and Behçet's syndrome in Britain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

Ocular immunopathology of Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

The arthritis of Behçet's disease: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

Behçet's disease and the nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

Clinical patterns of neurological involvement in Behçet's disease: evaluation of 200 patients. The Neuro-Behçet Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

Audio-vestibular evaluation in patients with Behçet's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

Neuropsychological follow-up of 12 patients with neuro-Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

Gastrointestinal manifestations of Behcet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

Vascular endothelial growth factor levels are increased and associated with disease activity in patients with Behçet's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

Intracardiac thrombus in Behçet's disease: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

Pulmonary complications of Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

Pulmonary manifestations in Behçet's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

Pulmonary manifestations of Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

Thoracic involvement in Behçet's disease and its correlation with multiple parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

Intestinal involvement in Behçet's disease: review of 136 surgical cases in the Japanese literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

Renal Behçet's disease: a cumulative analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

Urinary nitric oxide levels are increased and correlated with plasma concentrations in patients with Behçet's disease: is it a new urinary activity marker?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

IgA nephropathy in a patient with Behçet's syndrome--case report and review of literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

Behçet's disease and renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

Current therapy for Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

A double-blind trial of colchicine in Behçet's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

Azathioprine in Behcet's syndrome: effects on long-term prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

Short-term chlorambucil for refractory uveitis in Behcet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

Cyclosporin-A therapy in severe uveitis of Behçet's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

Ciclosporin microemulsion preconcentrate treatment of patients with Behçet's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

Treatment of Behçet disease with indomethacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

Chlorambucil in the treatment of uveitis and meningoencephalitis of Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

Low-dose weekly methotrexate for progressive neuropsychiatric manifestations in Behcet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

Central nervous system symptoms in patients with Behçet disease receiving cyclosporine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

Therapeutic effect of intraarterial prednisolone injection in severe intestinal Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behçet's disease: use of neurophysiological studies to detect thalidomide neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

Behçet's disease in UK children: clinical features and treatment including thalidomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

Effects of interferon alpha treatment on the clinical course of refractory Behçet's disease: an open study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

Effect of infliximab on sight-threatening panuveitis in Behçet's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

Anti-tumour necrosis factor alpha monoclonal antibody therapy for recalcitrant cerebral vasculitis in a patient with Behçet's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor alpha antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.2.317

21 January 2018

Identifiers

DOI

10.1517/14656566.5.2.317

1 reference

9 August 2017

1 reference